ClinicalTrials.gg
RecruitingNCT06513130PreGEDIUpdated Apr 29, 2025

Geriatric Assessment at Discharge From the Intensive Care Unit in Patients Aged 75 Years and Older: a Feasibility Study

An interventional study of Geriatric assessment in the 7 days following ICU discharge. and No geriatric assessment in the 7 days following ICU discharge. in Critical Illness, Geriatric Assessment and Older People, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2025-04-29.

Primary conditionFrailtyRegistry: Critical IllnessReclassifiedWhy we changed it
Registry
Critical Illness — the first condition term the registry derived for this study.
ClinicalTrials.gg
Frailty
Why
  1. Critical Illness is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Frailty.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University Hospital, Strasbourg, France · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
75 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Frailty with a site in France — 23 open to participants now, 25 under way, none of them phase 3. Frailty · France.

Planned enrollment
17th of 27
70 · median 106
Started
2024
with 5 others
No phase
27 of 59
9 open now
Primary completion
2027-01
later than 8 of 24 live
Registered
41st of 59
by date

Among the 59 studies in Frailty with a site in France, this one is the 17th largest by planned enrollment of the 27 interventional ones that give a count, is one of 6 that started in 2024, is one of 27 with no phase, reaches primary completion later than 8 of the 24 other live ones, and was the 41st registered.

Frailty

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

Browse Frailty studies →

Open to participants now

23 of the 59 studies in Frailty with a site in France are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.

This study: 75 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Frailty with a site in France, or all of them as a file.
02

Study summary

The number of patients aged over 75 continues to grow, and, according to INSEE, will represent almost 10% of the French population in 2021, an increase of 2.4 points since 2000. This demographic change is also observed in the intensive care units, where admitted patients aged over 80 represent now up to 10-20% of critical care admissions, depending on the facility.

The admission of these patients remains controversial, with questions about the benefit to elderly patients, both in terms of in-hospital and distant survival, as well as induced morbidity or subsequent quality of life: functional status is impaired in up to two-thirds of survivors.

The challenge of identifying the patients most able to withstand a stay is a major one. Indeed, a stay in intensive care represents a major stress for the organism, due to the acute condition associated with one or more organ failure(s). Bed rest, immobilization and the use of drugs are responsible for formidable complications in the elderly: muscle-wasting, loss of adaptation to physical effort, loss of autonomy, delirium and agitation, all of which have their own long-term impact.

While many studies have looked at the prognostic factors on admission of these patients, and the selection of the patient with the greatest probability of surviving the intensive care unit (ICU), improving the outcome of patients who survive to the ICU stay remains a little-investigated subject. However, the impact of physical and psychological disturbances induced by these patients' stay in intensive care is major, and their detection and management could be elements of interest in improving the care of this population. However, the feasibility of carrying out such an assessment immediately after an ICU stay has yet to be evaluated. The aim of this study would be to evaluate the feasibility of a geriatric assessment at the end of the ICU stay (or within 7 days of discharge) and at 6 months. This study is a prospective, randomized, single-center, open-label interventional study.

03

Conditions studied

  • Critical Illness
  • Geriatric Assessment
  • Older People
  • Frailty

Browse trials for

04

In context

Frailty Reclassified

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

This study's planned enrollment of 70 is below the median of 83 across 772 interventional studies indexed under Frailty.

Browse Frailty studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 1,000 studies on the registry; 359 are open to participants now.

Compared within Frailty, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over 75 years of age
  • Admitted to the intensive care unit, for whatever reason, and having survived their stay, considered as leaving the intensive care unit.
  • Subjects affiliated to a health insurance scheme
  • Able to understand the aims and risks of the research and to give dated, signed ,
  • In the event of confusion on leaving the intensive care unit, a close relative available to give dated, signed informed consent, with the patient's consent collected as soon as his or her condition permits.

Exclusion criteria

Exclusion Criteria:

  • Protected subject as defined by law: safeguard of justice, guardianship or curatorship procedures
  • Subject moribund, or whose as estimated by the clinician in charge is less than 1 month
  • Patient not living in Bas-Rhin (visit to M6)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Group with geriatric assessment

    Patients will be assessed by a geriatric physician, in a global (clinical, physical, psyochological and social) approach at the end of the ICU stay or in the 7 days following. In addition to the first visit in the group "without geriatric assessment", will be collected: * Living conditions (home, proxy, home support) * Quality of life (SF-36) * Covi test and 4-item Geriatric Depression Scale * Katz-ADL and IADL * History of fall, mobility assessment * Nutritional status (BMI, albuminemia, Mini Nutritionnal Assesment) * Cognitive assessment (Mini-mental State Examination) The visit at month 6 will be the same in both groups

    Other: Geriatric assessment in the 7 days following ICU discharge.

  • Active comparator
    Group without geriatric assessment

    At the end of the ICU stay or in the 7 days following, will be collect: * Medical and surgical history, Charlson comorbidity index, * Living place * Regular treatment (number and class) * ICU trajectory: ICU length of stay, reason for ICU admission, severity scores (SOFA and SAPS 2 score), organ supports requirement and duration * Limitation of life-sustaining therapy decision At 6 month after ICU discharge, patients will be evaluated during a post-ICU consultation, where will be recorded: * Living conditions (home, proxy, home support) * Quality of life (SF-36) * Covi test and 4-item Geriatric Depression Scale * Katz-ADL and IADL * History of fall, mobility assessment * Nutritional status (BMI, albuminemia, Mini Nutritionnal Assesment) * Cognitive assessment (Mini-mental State Examination) * Regular treatment (number and class) * Hospitalizations between ICU discharge and M6 * Additional comorbidity * Family burden assessment (mini-Zarit)

    Other: No geriatric assessment in the 7 days following ICU discharge.

Interventions

  • OtherGeriatric assessment in the 7 days following ICU discharge.

    ICU survivors will be assessed by a geriatric physician, in a global (clinical, physical, psyochological and social) approach at the end of the ICU stay or in the 7 days following ICU discharge.

  • OtherNo geriatric assessment in the 7 days following ICU discharge.

    No geriatric assessment in the 7 days following ICU discharge.

07

What researchers measure

Primary outcomes

  1. Rate of patients for whom a geriatric assessment is carried out between the end of their stay in intensive care and 7 days after discharge.

    Time frame: At 6 Month after ICU discharge

Secondary outcomes

  1. Rate of patients for whom consultation at M6 is carried out.

    Time frame: At 6 Month after ICU discharge

  2. Frailty, assessed using the Clinical Frailty Scale

    Time frame: At 6 Month after ICU discharge

  3. Total hospital length of stay

    Time frame: At 6 Month after ICU discharge

  4. Number of hospitalization

    Time frame: At 6 Month after ICU discharge

  5. Regular treatment modifications

    collection of current treatments on admission to intensive care, on discharge from intensive care and hospitalization, and at M6 (prescription)

    Time frame: At 6 Month after ICU discharge

  6. Modification of place of living

    location (single-family dwelling, retirement home, etc.)

    Time frame: At 6 Month after ICU discharge

  7. Evolution of the quality of life assessed by the SF-36 questionnary

    For the interventional arm

    Time frame: At 6 Month after ICU discharge

  8. Evolution of the psychological behaviours through the mini Geriatric depression score evolution and the Covi test evolution for the anxiety component.

    For the interventional arm

    Time frame: At 6 Month after ICU discharge

  9. Evolution of the psychological behaviours through the Covi test evolution for the anxiety component.

    For the interventional arm

    Time frame: At 6 Month after ICU discharge

  10. Evolution of the Katz-ADL score between initial assessment and month 6

    For the interventional arm For the control arm,

    Time frame: At 6 Month after ICU discharge

  11. Evolution of the IADL score between initial assessment and month 6

    For the interventional arm For the control arm,

    Time frame: At 6 Month after ICU discharge

  12. Evolution of the locomotor abilities

    Time frame: At 6 Month after ICU discharge

  13. Evolution of cognition evaluation: mini Mental State Examination

    Time frame: At 6 Month after ICU discharge

  14. At M6: main organ function assessment

    Time frame: At 6 Month after ICU discharge

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jan 2027, 26 months after the start.

Of 514 non-industry interventional studies with no phase under Frailty, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's planned 26 months is above that.

Counting every sponsor, half of 519 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2024
First posted
Jul 22, 2024
StartActual
Nov 1, 2024
Primary completionEst.
Jan 2, 2027
CompletionEst.
Jan 2, 2027
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06513130
Responsible party
Sponsor
First posted
Jul 22, 2024
Start date
Nov 1, 2024
Primary completion
Jan 2, 2027 (estimated)
Completion
Jan 2, 2027 (estimated)
Last update
Apr 29, 2025

Study contacts

Julien DEMISELLE
Contact
julien.demiselle@chru-strasbourg.fr
0369551079 ext. +33
Julien DEMISELLE
principal investigator · Hôpitaux Universitaires de Strasbourg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion